Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2009 2
2011 1
2012 1
2014 2
2015 2
2016 2
2017 2
2018 1
2019 5
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year
Filters applied: . Clear all
Page 1
A Ubiquitous Platform for Bacterial Nanotube Biogenesis.
Bhattacharya S, Baidya AK, Pal RR, Mamou G, Gatt YE, Margalit H, Rosenshine I, Ben-Yehuda S. Bhattacharya S, et al. Among authors: pal rr. Cell Rep. 2019 Apr 9;27(2):334-342.e10. doi: 10.1016/j.celrep.2019.02.055. Epub 2019 Mar 28. Cell Rep. 2019. PMID: 30929979 Free PMC article.
Credible Protein Targets and Curative Strategies for COVID-19: a Review.
Singh P, Mishra N, Singh N, Nisha R, Pal RR, Singh S, Maurya P, Saraf SA. Singh P, et al. Among authors: pal rr. SN Compr Clin Med. 2020 Sep 25:1-10. doi: 10.1007/s42399-020-00526-3. Online ahead of print. SN Compr Clin Med. 2020. PMID: 33015546 Free PMC article. Review.
Enteropathogenic Escherichia coli remodels host endosomes to promote endocytic turnover and breakdown of surface polarity.
Kassa EG, Zlotkin-Rivkin E, Friedman G, Ramachandran RP, Melamed-Book N, Weiss AM, Belenky M, Reichmann D, Breuer W, Pal RR, Rosenshine I, Lapierre LA, Goldenring JR, Aroeti B. Kassa EG, et al. Among authors: pal rr. PLoS Pathog. 2019 Jun 26;15(6):e1007851. doi: 10.1371/journal.ppat.1007851. eCollection 2019 Jun. PLoS Pathog. 2019. PMID: 31242273 Free PMC article.
Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.
Ramdas V, Talwar R, Kanoje V, Loriya RM, Banerjee M, Patil P, Joshi AA, Datrange L, Das AK, Walke DS, Kalhapure V, Khan T, Gote G, Dhayagude U, Deshpande S, Shaikh J, Chaure G, Pal RR, Parkale S, Suravase S, Bhoskar S, Gupta RV, Kalia A, Yeshodharan R, Azhar M, Daler J, Mali V, Sharma G, Kishore A, Vyawahare R, Agarwal G, Pareek H, Budhe S, Nayak A, Warude D, Gupta PK, Joshi P, Joshi S, Darekar S, Pandey D, Wagh A, Nigade PB, Mehta M, Patil V, Modi D, Pawar S, Verma M, Singh M, Das S, Gundu J, Nemmani K, Bock MG, Sharma S, Bakhle D, Kamboj RK, Palle VP. Ramdas V, et al. Among authors: pal rr. J Med Chem. 2020 Jun 11;63(11):6107-6133. doi: 10.1021/acs.jmedchem.0c00361. Epub 2020 May 19. J Med Chem. 2020. PMID: 32368909
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.
van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubel A, Dummer R. van Herpen CML, et al. Among authors: pal rr. Oncotarget. 2019 Mar 5;10(19):1850-1859. doi: 10.18632/oncotarget.26753. eCollection 2019 Mar 5. Oncotarget. 2019. PMID: 30956763 Free PMC article.
24 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page